What's Happening?
AstraZeneca and Ionis Pharmaceuticals have announced that their transthyretin amyloidosis (ATTR) therapy, Wainua, did not meet its primary endpoint in a phase 3 trial for patients with cardiomyopathy (CM). The trial, known as CARDIO-TTRansform, aimed
to evaluate the efficacy of Wainua in improving cardiovascular mortality and recurrent clinical events over 140 weeks. Despite being approved for the polyneuropathy form of ATTR, Wainua failed to show significant improvement in the cardiomyopathy form, impacting its commercial prospects. The trial's failure has led to a significant drop in AstraZeneca's and Ionis' share prices, with Ionis experiencing a 17% decline. The results will be further analyzed and presented at the European Society of Cardiology annual congress.
Why It's Important?
The failure of Wainua in the CARDIO-TTRansform trial is significant as it affects the drug's potential to capture a larger market share in the ATTR-CM segment, which has a much larger patient population compared to ATTR-PN. The setback could impact projected peak sales, which were initially estimated at $6.5 billion. This development also highlights the competitive landscape in the ATTR-CM market, where existing treatments like Pfizer's Vyndamax are already achieving blockbuster sales. The trial's outcome underscores the challenges in developing effective treatments for complex conditions like ATTR-CM, which require innovative approaches to meet unmet medical needs.
What's Next?
AstraZeneca and Ionis plan to conduct a detailed analysis of the trial data to understand the reasons behind the failure. The results will be shared at the upcoming European Society of Cardiology congress, which may provide insights into future treatment strategies for ATTR-CM. Despite the setback, AstraZeneca remains focused on its other ongoing trials, such as the SERENA-4 and AVANZAR studies, which could potentially deliver positive results and contribute to the company's growth targets.
